Japan's Fujitsu, Mizuho, PeptiDream to form joint venture to develop COVID-19 treatments

PeptiDream

12/11/2020 03:00

TOKYO, Nov 12 (Reuters) - Fujitsu Ltd, Mizuho Financial
Group Inc, and drugmaker PeptiDream Inc said on Thursday they
are forming a joint venture to develop treatments for COVID-19.
    The new company, to be called PeptiAID Inc, will research
and develop peptide therapeutics for the current SARS-CoV-2
virus and potential future coronavirus outbreaks, the companies
said in a release.
    The joint venture also includes Takenaka Corp and Kishida
Chemical Co.


 (Reporting by Rocky Swift; Editing by Kim Coghill)
 ((rocky.swift@thomsonreuters.com;))